Stem Cell-Based Human Blood-Brain Barrier Models for Drug Discovery and Delivery

Trends in Biotechnology

Volumn 34, Issue 5, 2016, Pages 382-393

  Aday, S ^a,b,c   Cecchelli, R ^d   Hallier Vanuxeem, D ^d   Dehouck, M P ^d   Ferreira, L ^a,b,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Biocant Center of Innovation in Biotechnology   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITÉ D'ARTOIS   (France)

Author keywords

Blood brain barrier; In vitro models; Neurodegenerative diseases; Neuropharmaceuticals; Stem cells

Indexed keywords

BLOOD; DIAGNOSIS; DRUG PRODUCTS; GLYCOPROTEINS; MAMMALS; NEURODEGENERATIVE DISEASES;

BLOOD-BRAIN BARRIER; CLINICAL STUDY; DRUG DEVELOPMENT; IN-VITRO MODELS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEUROPHARMACEUTICALS; P-GLYCOPROTEIN; PLURIPOTENT STEM CELLS;

STEM CELLS;

AMINO ACID TRANSPORTER; GLUCOSE TRANSPORTER 1; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MONOCARBOXYLATE TRANSPORTER 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER 3; TRANSFERRIN RECEPTOR;

ADULT; BLOOD BRAIN BARRIER; BRAIN CELL; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL; TIGHT JUNCTION; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; DRUG DEVELOPMENT; METABOLISM; MOUSE; PHYSIOLOGY; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DRUG DISCOVERY; HUMANS; MICE; MODELS, BIOLOGICAL; P-GLYCOPROTEINS; STEM CELLS;

EID: 84978012432     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2016.01.001     Document Type: Review

References (69)

1. Cecchelli R., et al. Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug Discov. 2007, 6:650-661.
2. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 2003, 3:90-105.
3. Ghose A.K., et al. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1999, 1:55-68.
4. Hoshi Y., et al. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J. Pharm. Sci. 2013, 102:3343-3355.
5. Ito K., et al. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J. Pharm. Sci. 2011, 100:3939-3950.
6. Shawahna R., et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm. 2011, 8:1332-1341.
7. Uchida Y., et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 2011, 117:333-345.
8. Uchida Y., et al. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS 2013, 10:21.
9. Syvanen S., et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab. Dispos. 2009, 37:635-643.
10. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
11. Hsiao P., et al. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J. Pharm. Exp. Ther. 2006, 317:704-710.
12. 11C]verapamil. J. Pharmacol. Exp. Ther. 2006, 316:647-653.
13. Lippmann E.S., et al. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat. Biotechnol. 2012, 30:783-791.
14. Boyer-Di Ponio J., et al. Instruction of circulating endothelial progenitors in vitro towards specialized blood-brain barrier and arterial phenotypes. PLoS ONE 2014, 9:e84179.
15. Cecchelli R., et al. A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells. PLoS ONE 2014, 9:e99733.
16. Lippmann E.S., et al. A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sources. Sci. Rep. 2014, 4:4160.
17. Ballabh P., et al. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 2004, 16:1-13.
18. Cardoso F.L., et al. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res. Rev. 2010, 64:328-363.
19. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 2010, 37:48-57.
20. Liddelow S.A. Fluids and barriers of the CNS: a historical viewpoint. Fluids Barriers CNS 2011, 8:2.
21. Wilhelm I., et al. In vitro models of the blood-brain barrier. Acta Neurobiol. Exp. 2011, 71:113-128.
22. Abbott N.J., et al. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
23. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005, 57:173-185.
24. Deeken J.F., Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 2007, 13:1663-1674.
25. Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 2002, 200:629-638.
26. Joo F. Endothelial cells of the brain and other organ systems: some similarities and differences. Prog. Neurobiol. 1996, 48:255-273.
27. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul. Pharmacol. 2002, 38:323-337.
28. Butt A.M., et al. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J. Physiol. 1990, 429:47-62.
29. Hirase T., et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J. Cell Sci. 1997, 110:1603-1613.
30. Betz A.L., et al. Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. Brain Res. 1980, 192:17-28.
31. Tewes B.J., Galla H-J. Membrane fractionation of brain capillary endothelial cells and analysis of lipid polarity. Biology and Physiology of the Blood-Brain Barrier 1996, 97-101. Plenum Press. P. Couraud, D. Scherman (Eds.).
32. Kamiie J., et al. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res. 2008, 25:1469-1483.
33. +/glucose co-transporter (SGLT1) is dissociated from mRNA abundance. Biochem. J. 1993, 291:435-440.
34. Molina-Arcas M., et al. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 2005, 19:64-68.
35. Elsinga P.H., et al. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr. Pharm. Des. 2004, 10:1493-1503.
36. 11C]leucine and PET: methods, model, and results in animals and humans. J. Cereb. Blood Flow Metab. 1989, 9:446-460.
37. Hendrikse N.H., et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 1999, 59:2411-2416.
38. Hendrikse N.H., et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol. 1998, 124:1413-1418.
39. Cremer J.E., et al. Kinetics of blood-brain barrier transport of pyruvate, lactate and glucose in suckling, weanling and adult rats. J. Neurochem. 1979, 33:439-445.
40. Ohtsuki S., Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 2007, 24:1745-1758.
41. Irifune M., et al. Effects of ketamine on dopamine metabolism during anesthesia in discrete brain regions in mice: comparison with the effects during the recovery and subanesthetic phases. Brain Res. 1997, 763:281-284.
42. Young L.T., et al. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol. Psychiatry 1994, 35:121-127.
43. Furuse M., et al. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell Biol. 1998, 141:1539-1550.
44. Furuse M., et al. A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J. Cell Biol. 1998, 143:391-401.
45. Morita K., et al. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J. Cell Biol. 1999, 147:185-194.
46. Pfeiffer F., et al. Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis. Acta Neuropathol. 2011, 122:601-614.
47. Liebner S., et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000, 100:323-331.
48. Ohtsuki S., et al. mRNA expression levels of tight junction protein genes in mouse brain capillary endothelial cells highly purified by magnetic cell sorting. J. Neurochem. 2008, 104:147-154.
49. Nitta T., et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 2003, 161:653-660.
50. Chen X., et al. Ischemia-reperfusion impairs blood-brain barrier function and alters tight junction protein expression in the ovine fetus. Neuroscience 2012, 226:89-100.
51. Urich E., et al. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS ONE 2012, 7:e38149.
52. Ohtsuki S., et al. Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol. Pharm. 2013, 10:289-296.
53. Sano Y., et al. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J. Cell Physiol. 2010, 225:519-528.
54. Weksler B.B., et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005, 19:1872-1874.
55. Lippmann E.S., et al. Blood-brain barrier modeling with co-cultured neural progenitor cell-derived astrocytes and neurons. J. Neurochem. 2011, 119:507-520.
56. Friden M., et al. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab. Dispos. 2007, 35:1711-1719.
57. Friden M., et al. Structure-brain exposure relationships in rat and human using a novel dta set of unbound drug concentrations in brain interstitial and cerebrospinal. J. Med. Chem. 2009, 52:10.
58. Pehlivan S.B. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm. Res. 2013, 30:2499-2511.
59. Bramini M., et al. Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier. ACS Nano 2014, 8:4304-4312.
60. Hall M.D., Pike V.W. Avoiding barriers to PET radioligand development: cellular assays of brain efflux transporters. J. Nucl. Med. 2011, 52:338-340.
61. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005, 2:3-14.
62. Pardridge W.M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 2012, 32:1959-1972.
63. Bhowmik A., et al. Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed. Res. Int. 2015, 2015:320941.
64. Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013, 2013:238428.
65. Stenehjem D.D., et al. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Future Med. Chem. 2009, 1:1623-1641.
66. Griep L.M., et al. BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomed. Microdevices 2013, 15:145-150.
67. Prabhakarpandian B., et al. SyM-BBB: a microfluidic blood brain barrier model. Lab Chip 2013, 13:1093-1101.
68. Robinton D.A., Daley G.Q. The promise of induced pluripotent stem cells in research and therapy. Nature 2012, 481:295-305.
69. Georgieva J.V., et al. Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro. Mol. Ther. 2011, 19:318-325.